Axatilimab + Decitabine/Venetoclax for Acute Myeloid Leukemia

This trial explores a new combination of treatments—Axatilimab (an experimental treatment), Decitabine, and Venetoclax—to determine their effectiveness in treating acute myeloid leukemia (AML) with a specific genetic change in the TP53 gene. In some individuals with AML, the TP53 gene may be mutated or deleted. This trial targets those who have either not yet received treatment or whose cancer has returned after initial treatment. Individuals diagnosed with AML and a TP53 mutation or deletion may find this trial suitable. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment combination.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Studies have shown that using Venetoclax and Decitabine together is generally safe for treating acute myeloid leukemia (AML). This combination has proven effective and well-tolerated in older patients with AML. Reports indicate that most patients experience manageable side effects, meaning the treatment doesn't cause severe problems for most people.

Researchers are excited about the combination of Axatilimab, Decitabine, and Venetoclax for treating Acute Myeloid Leukemia (AML) because it offers a fresh approach compared to existing treatments. Unlike traditional chemotherapy, which broadly attacks both healthy and cancerous cells, this combination targets specific pathways involved in cancer cell survival and growth. Axatilimab is notable for its action on the CSF-1R pathway, potentially reducing the immune system's suppression by the leukemia cells. Decitabine and Venetoclax complement this by disrupting the cancer cells' DNA repair and survival mechanisms. This targeted approach not only aims to be more effective but also may result in fewer side effects, making it an exciting development in AML treatment.

Research has shown that using Decitabine and Venetoclax together holds promise for treating acute myeloid leukemia (AML). In one study, 90% of patients achieved complete remission, with no detectable cancer. Another study found these drugs more effective than strong chemotherapy for older patients. In this trial, participants will receive a combination of Axatilimab, Decitabine, and Venetoclax. Adding Axatilimab may enhance the immune system, though limited data exists on this combination. Overall, Decitabine and Venetoclax have demonstrated strong potential in treating AML.³⁵⁶⁷⁸